448 related articles for article (PubMed ID: 26243232)
1. Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study.
Kim BJ; Han MK; Park TH; Park SS; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Lee J; Lee SJ; Ko Y; Park JM; Kang K; Cho YJ; Hong KS; Kim JT; Choi JC; Kim DE; Shin DI; Kim WJ; Lee J; Lee JS; Yoon BW; Gorelick PB; Bae HJ
Stroke; 2015 Sep; 46(9):2541-8. PubMed ID: 26243232
[TBL] [Abstract][Full Text] [Related]
2. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
[TBL] [Abstract][Full Text] [Related]
5. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
[TBL] [Abstract][Full Text] [Related]
6. Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study.
Wang X; Li J; Moullaali TJ; Lee KJ; Kim BJ; Bae HJ; Wang A; Wang Y; Wang DZ; Wang Y; Kumamoto M; Toyoda K; Koga M; Sato S; Yoshimura S; Sui Y; Xu B; Xiao Y; Lee TH; Liou CW; Lee JD; Peng TI; Huang YC; Paliwal PR; Sharma M; Escabillas C; Navarro JC; Sun MC; Dong Y; Dong Q; Anderson CS; Sharma VK
Int J Stroke; 2019 Oct; 14(7):670-677. PubMed ID: 31226919
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety.
Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z
Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of thrombolysis with intravenous alteplase for acute ischemic stroke in daily practice.
Dirks M; Niessen LW; van Wijngaarden J; Koudstaal PJ; Franke CL; van Oostenbrugge RJ; Dippel DW;
Int J Stroke; 2012 Jun; 7(4):289-92. PubMed ID: 22168317
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
[TBL] [Abstract][Full Text] [Related]
10. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG;
Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832
[TBL] [Abstract][Full Text] [Related]
11. Comparing Low- or Standard-Dose Alteplase in Endovascular Thrombectomy: Insights From a Nationwide Registry.
Chen CH; Lee CW; Hsieh YC; Lin CJ; Chen YW; Lin KH; Sung PS; Tang CW; Chu HJ; Tsai KC; Chou CL; Lin CH; Wei CY; Yen SY; Chen PL; Yeh HL; Chan L; Sung SF; Lee M; Liu HM; Lin YH; Lee IH; Yeh SJ; Lien LM; Chiou HY; Lee JT; Tang SC; Jeng JS;
Stroke; 2024 Mar; 55(3):532-540. PubMed ID: 38314590
[TBL] [Abstract][Full Text] [Related]
12. Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) Recombinant tissue plasminogen activator registry.
Miyagi T; Koga M; Shiokawa Y; Nakagawara J; Hasegawa Y; Furui E; Kimura K; Kario K; Okuda S; Yamagami H; Okada Y; Nezu T; Maeda K; Endo K; Minematsu K; Toyoda K
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1098-106. PubMed ID: 23063059
[TBL] [Abstract][Full Text] [Related]
13. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
[TBL] [Abstract][Full Text] [Related]
14. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B
J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of standard care with IV thrombolysis versus without IV thrombolysis for mild ischemic stroke.
Choi JC; Jang MU; Kang K; Park JM; Ko Y; Lee SJ; Cha JK; Kim DH; Park SS; Park TH; Lee KB; Lee J; Kim JT; Cho KH; Yu KH; Oh MS; Lee BC; Cho YJ; Kim DE; Lee JS; Lee J; Gorelick PB; Bae HJ
J Am Heart Assoc; 2015 Jan; 4(1):e001306. PubMed ID: 25628404
[TBL] [Abstract][Full Text] [Related]
16. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS).
Nakagawara J; Minematsu K; Okada Y; Tanahashi N; Nagahiro S; Mori E; Shinohara Y; Yamaguchi T;
Stroke; 2010 Sep; 41(9):1984-9. PubMed ID: 20651262
[TBL] [Abstract][Full Text] [Related]
17. Current status of intravenous thrombolysis for acute ischemic stroke in Asia.
Sharma VK; Ng KW; Venketasubramanian N; Saqqur M; Teoh HL; Kaul S; Srivastava PM; Sergentanis T; Suwanwela N; Nguyen TH; Lawrence Wong KS; Chan BP
Int J Stroke; 2011 Dec; 6(6):523-30. PubMed ID: 22111797
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Thrombolysis in Unknown-Onset Stroke: Results From the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry.
Dorado L; Ahmed N; Thomalla G; Lozano M; Malojcic B; Wani M; Millán M; Tomek A; Dávalos A
Stroke; 2017 Mar; 48(3):720-725. PubMed ID: 28174326
[TBL] [Abstract][Full Text] [Related]
19. Low body temperature does not compromise the treatment effect of alteplase.
Lees JS; Mishra NK; Saini M; Lyden PD; Shuaib A;
Stroke; 2011 Sep; 42(9):2618-21. PubMed ID: 21757664
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
Wang X; Robinson TG; Lee TH; Li Q; Arima H; Bath PM; Billot L; Broderick J; Demchuk AM; Donnan G; Kim JS; Lavados P; Lindley RI; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sharma VK; Thang NH; Wang JG; Woodward M; Anderson CS; Chalmers J;
JAMA Neurol; 2017 Nov; 74(11):1328-1335. PubMed ID: 28973174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
